Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases.

Department of Surgical Research, Technical University of Dresden, Germany. -dresden-de
Clinical Cancer Research (Impact Factor: 7.84). 10/1999; 5(9):2431-7.
Source: PubMed

ABSTRACT The high mutation rate in advanced brain tumors, recent functional studies, and the high frequency of mutations in prostate metastases all strongly suggest that PTEN/MMAC1 alterations are involved in the formation of metastases. We searched for genetic alterations in the PTEN/MMAC1 gene in 56 consecutive brain metastases from various primary tumors by loss of heterozygosity (LOH), direct sequence analysis, and differential PCR analysis. The highest LOH rates were detected in metastases deriving from lung (67%) and breast (64%) cancers. Three (25%) of the eight detected inactivating mutations (one nonsense mutation, one splice-site mutation, one 11-bp deletion, and five homozygous deletions) were found in metastases originating from 12 different lung carcinomas, suggesting that PTEN/MMAC1 alterations may play a role in the progression of this tumor. With the exception of lung carcinomas, our findings indicate that genetic abnormalities of the PTENM/MMAC1 gene are only involved in a relatively small subset of brain metastases. However, the discrepancy between the high overall LOH rate (50%) and the low frequency of PTEN/MMAC1 mutation detection rate (14%) suggests the presence of one or more additional tumor suppressor genes on chromosome 10q.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Die Inaktivierung von p16 und p14ARF wird als bedeutender Schritt der Tumorgenese des Oropharynxkarzinoms angesehen. Allelverluste in der Region dieser Gene werden in Mundschleimhautkarzinomen und deren Vorläuferläsionen angetroffen. Die vorliegende Studie sollte prüfen, in welchem Umfang Allelverluste bereits in Mundschleimhautleukoplakien auftreten und ob es anhand dieser Veränderungen möglich ist, Leukoplakien mit und ohne maligne Entartung zu unterscheiden. Darüber hinaus sollten geklärt werden, ob betroffene Leukoplakien Sequenzveränderungen der Gene p16 und p14ARF tragen, die eine Beeinträchtigung der Genfunktion bewirken können. Die Ergebnisse zeigten, dass „LOH“ (loss of heterozygosity) in Region der Gene p16 und p14ARF sowohl in Leukoplakien mit maligner Entartung als auch in klinisch entartungsfreien Leukoplakien auftreten, wobei sich die Allelverlusthäufigkeiten nicht signifikant unterscheiden. Insgesamt wurden in Leukoplakien seltener Allelverluste angetroffen als in den resultierenden Mundschleimhautkarzinomen (p
    Mund- Kiefer- und Gesichtschirurgie 01/2007; 11(6):317-326.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gain-of-function mutations in oncogenes and loss-of-function mutations in tumor suppressor genes (TSG) lead to cancer. In most human cancers, these mutations occur in somatic tissues. However, hereditary forms of cancer exist for which individuals are heterozygous for a germline mutation in a TSG locus at birth. The second allele is frequently inactivated by gene deletion, point mutation, or promoter methylation in classical TSGs that meet Knudson's two-hit hypothesis. Conversely, the second allele remains as wild-type, even in tumors in which the gene is haplo-insufficient for tumor suppression. This article highlights the importance of PTEN, APC, and other tumor suppressors for counteracting aberrant PI3K, β-catenin, and other oncogenic signaling pathways. We discuss the use of gene-engineered mouse models (GEMM) of human cancer focusing on Pten and Apc knockout mice that recapitulate key genetic events involved in initiation and progression of human neoplasia. Finally, the therapeutic potential of targeting these tumor suppressor and oncogene signaling networks is discussed.
    Clinical Medicine Insights: Oncology 01/2013; 7:103-122.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastoma is the most frequent and malignant human brain tumor. High level of genomic instability detected in glioma cells implies that numerous genetic alterations accumulate during glioma pathogenesis. We investigated alterations in AP-PCR DNA profiles of 30 glioma patients, and detected specific changes in 11 genes not previously associated with this disease: LHFPL3, SGCG, HTR4, ITGB1, CPS1, PROS1, GP2, KCNG2, PDE4D, KIR3DL3, and INPP5A. Further correlations revealed that 8 genes might play important role in pathogenesis of glial tumors, while changes in GP2, KCNG2 and KIR3DL3 should be considered as passenger mutations, consequence of high level of genomic instability. Identified genes have a significant role in signal transduction or cell adhesion, which are important processes for cancer development and progression. According to our results, LHFPL3 might be characteristic of primary glioblastoma, SGCG, HTR4, ITGB1, CPS1, PROS1 and INPP5A were detected predominantly in anaplastic astrocytoma, suggesting their role in progression of secondary glioblastoma, while alterations of PDE4D seem to have important role in development of both glioblastoma subtypes. Some of the identified genes showed significant association with p53, p16, and EGFR, but there was no significant correlation between loss of PTEN and any of identified genes. In conclusion our study revealed genetic alterations that were not previously associated with glioma pathogenesis and could be potentially used as molecular markers of different glioblastoma subtypes.
    PLoS ONE 01/2013; 8(12):e82108. · 3.53 Impact Factor